Shaanxi Panlong Pharmaceutical Group Limited By Share Ltd Class A (002864) — Strategic Asset Allocation Index
Shaanxi Panlong Pharmaceutical Group Limited By Share Ltd Class A (002864) has a Strategic Asset Allocation Index of 23.8% as of September 2023. Strategic assets (PP&E of CN¥363.54 Million plus long-term investments of CN¥-) total CN¥363.54 Million, measured against net assets of CN¥1.53 Billion. A higher index reflects capital-intensive or investment-heavy strategies where strategic assets dominate the equity base. See how leveraged is Shaanxi Panlong Pharmaceutical Group Lim's balance sheet to measure how much of total assets are equity-financed.
SAAI
Strategic Assets
PP&E
Net Assets
Shaanxi Panlong Pharmaceutical Group Limited By Share Ltd Class A Strategic Asset Allocation Index (2016–2022)
This chart shows how Shaanxi Panlong Pharmaceutical Group Limited By Share Ltd Class A's Strategic Asset Allocation Index has evolved across 7 annual periods from 2016 to 2022. As of September 2023, the index stands at 23.8%, representing strategic assets of CN¥363.54 Million against net assets of CN¥1.53 Billion CNY. For live market cap and overall valuation, see Shaanxi Panlong Pharmaceutical Group Lim market capitalisation.
Annual Strategic Asset Allocation Index for Shaanxi Panlong Pharmaceutical Group Limited By Share Ltd Class A (2016–2022)
The table below presents the year-by-year Strategic Asset Allocation Index for Shaanxi Panlong Pharmaceutical Group Limited By Share Ltd Class A from 2016 to 2022, covering 7 annual filings. Each row shows PP&E, long-term investments, strategic assets combined, net assets, the index percentage, and the change in percentage points compared to the prior year. See Shaanxi Panlong Pharmaceutical Group Lim book value and equity for net asset value and shareholders' equity analysis.
| Year | SAAI | Strategic Assets (CNY) | PP&E | LT Investments | Net Assets | Change (pp) |
|---|---|---|---|---|---|---|
| 2022 | 37.3% | CN¥353.74 Million | CN¥353.74 Million | CN¥- | CN¥947.60 Million | ▲ +3.3 pp |
| 2021 | 34.1% | CN¥275.04 Million | CN¥275.04 Million | CN¥- | CN¥807.21 Million | ▲ +7.2 pp |
| 2020 | 26.8% | CN¥197.40 Million | CN¥197.40 Million | CN¥- | CN¥735.66 Million | ▲ +5.5 pp |
| 2019 | 21.4% | CN¥144.20 Million | CN¥144.20 Million | CN¥- | CN¥674.71 Million | ▼ -1.8 pp |
| 2018 | 23.2% | CN¥141.76 Million | CN¥141.76 Million | CN¥- | CN¥611.60 Million | ▼ -2.1 pp |
| 2017 | 25.3% | CN¥140.32 Million | CN¥140.32 Million | CN¥- | CN¥555.58 Million | ▼ -13.5 pp |
| 2016 | 38.8% | CN¥127.03 Million | CN¥127.03 Million | CN¥- | CN¥327.82 Million | — |